{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:25:11Z","timestamp":1793345111559,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An increased risk of atherosclerotic and thrombotic complications characterizes connective tissue diseases. Endothelial dysfunction is the basis for the initiation and progression of atherosclerosis and thrombosis. We present systemic lupus erythematosus (SLE) as a model rheumatic disease with endothelial dysfunction and discuss its mechanisms, factors that influence the early onset and rapid progression of atherosclerosis, and the increased risk of thromboembolic events. We focus on established methods to improve endothelium function, including statins, antiplatelet, and antithrombotic therapy. Hypercoagulable and hypofibrinolitic states and a hyperinflammatory response characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several pathogenic mechanisms are typical for an acute phase of Covid-19 post-Covid syndrome and connective tissue diseases: endothelial dysfunction, elevated antiphospholipid antibody titer, activation of the complement system, and formation of extracellular neutrophil traps (NET). The current review discusses the mechanisms underlying SLE and the COVID-19 in the context of endothelial function, atherosclerosis, and thrombosis (Graphical abstract).\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>Key Points<\/jats:bold>\n                              <jats:italic>\u2022 The pathophysiology of systemic lupus erythematosus (SLE) and Covid-19 shows some similarities, such as endothelial cell activation and dysfunction, the activation of complementary systems, the presence of antiphospholipid antibodies, and the formation of extracellular neutrophil traps.<\/jats:italic>\n                              <jats:italic>\u2022 Autoimmunity in both diseases creates the basis for hyperinflammatory, hypercoagulable, and hypofibrinolitic states and their thromboembolic complications.<\/jats:italic>\n                              <jats:italic>\u2022 This paper presents our perspective on the mechanisms behind the cardiovascular manifestations of SLE and COVID-19, with a particular emphasis on endothelial dysfunction.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Covid-19 and systemic lupus erythematosus\u2014potential similarities in pathophysiology. Figures of the panel illustrate the clinical manifestations of endothelial dysfunction, atherosclerosis, and thromboembolism, including coronary artery disease ([A] coronary angiography with left anterior descending artery stenosis and [B] scintigraphy with reduced perfusion in the myocardial apical segments), stroke ([C] carotid angiography, left carotid artery occlusion) and pulmonary embolism ([D]computed tomography with thrombus in the right pulmonary artery).<\/jats:p>","DOI":"10.1007\/s10067-022-06497-1","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:05:56Z","timestamp":1673222756000},"page":"2691-2702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-8206","authenticated-orcid":false,"given":"Wojciech","family":"P\u0142azak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-7168","authenticated-orcid":false,"given":"Leszek","family":"Drabik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"6497_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1161\/01.cir.25.5.869","volume":"25","author":"P Klemperer","year":"1962","unstructured":"Klemperer P (1962) The concept of connective-tissue disease. Circulation 25:869\u2013871. https:\/\/doi.org\/10.1161\/01.cir.25.5.869","journal-title":"Circulation"},{"key":"6497_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0002-9343(76)90431-9","volume":"60","author":"MB Urowitz","year":"1976","unstructured":"Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221\u2013225. https:\/\/doi.org\/10.1016\/0002-9343(76)90431-9","journal-title":"Am J Med"},{"key":"6497_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0146-2806(99)90019-1","volume":"24","author":"WC Roberts","year":"1999","unstructured":"Roberts WC, High ST (1999) The heart in systemic lupus erythematosus. Curr Probl Cardiol 24:1\u201356. https:\/\/doi.org\/10.1016\/s0146-2806(99)90019-1","journal-title":"Curr Probl Cardiol"},{"key":"6497_CR4","first-page":"1265","volume":"22","author":"M Abu-Shakra","year":"1995","unstructured":"Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22:1265\u201370","journal-title":"J Rheumatol"},{"key":"6497_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ard.61.12.1065","volume":"61","author":"K Manger","year":"2002","unstructured":"Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A et al (2002) Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61:1065\u20131070. https:\/\/doi.org\/10.1136\/ard.61.12.1065","journal-title":"Ann Rheum Dis"},{"key":"6497_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","volume":"145","author":"S Manzi","year":"1997","unstructured":"Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TAJ, Jansen-McWilliams L et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408\u2013415. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009122","journal-title":"Am J Epidemiol"},{"key":"6497_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00011-011-0358-x","volume":"60","author":"W Plazak","year":"2011","unstructured":"Plazak W, Pasowicz M, Kostkiewicz M, Podolec J, Tomkiewicz-Pajak L, Musial J et al (2011) Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients. Inflamm Res 60:973\u2013980. https:\/\/doi.org\/10.1007\/s00011-011-0358-x","journal-title":"Inflamm Res"},{"key":"6497_CR8","doi-asserted-by":"publisher","first-page":"6813016","DOI":"10.1155\/2016\/6813016","volume":"2016","author":"X Yang","year":"2016","unstructured":"Yang X, Chang Y, Wei W (2016) Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediators Inflamm 2016:6813016. https:\/\/doi.org\/10.1155\/2016\/6813016","journal-title":"Mediators Inflamm"},{"key":"6497_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1573397115666181126105318","volume":"15","author":"E Sciatti","year":"2019","unstructured":"Sciatti E, Cavazzana I, Vizzardi E, Bonadei I, Fredi M, Taraborelli M et al (2019) Systemic lupus erythematosus and endothelial dysfunction: a close relationship. Curr Rheumatol Rev 15:177\u2013188. https:\/\/doi.org\/10.2174\/1573397115666181126105318","journal-title":"Curr Rheumatol Rev"},{"key":"6497_CR10","doi-asserted-by":"publisher","first-page":"9680729","DOI":"10.1155\/2017\/9680729","volume":"2017","author":"L Atehort\u00faa","year":"2017","unstructured":"Atehort\u00faa L, Rojas M, V\u00e1squez GM, Casta\u00f1o D (2017) Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediators Inflamm 2017:9680729. https:\/\/doi.org\/10.1155\/2017\/9680729","journal-title":"Mediators Inflamm"},{"key":"6497_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00296-022-05104-5","volume":"42","author":"P Cie\u015blik","year":"2022","unstructured":"Cie\u015blik P, Semik-Grabarczyk E, Hrycek A, Holecki M (2022) The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study. Rheumatol Int 42:791\u2013801. https:\/\/doi.org\/10.1007\/s00296-022-05104-5","journal-title":"Rheumatol Int"},{"key":"6497_CR12","doi-asserted-by":"publisher","unstructured":"Foret T, Dufrost V, Heymonet M, Risse J, Faure G, Louis H, et al (2022) Circulating endothelial cells are associated with thromboembolic events in patients with antiphospholipid antibodies. Thromb Haemost. Online ahead of print. https:\/\/doi.org\/10.1055\/a-1926-0453","DOI":"10.1055\/a-1926-0453"},{"key":"6497_CR13","first-page":"348","volume":"22","author":"M Adawi","year":"2020","unstructured":"Adawi M, Abu-Gabel T, Sabbah F, Yehuda I, Tamir S, Blum A (2020) Vascular reactivity of adult-onset systemic lupus erythematosus patients. Isr Med Assoc J 22:348\u2013351","journal-title":"Isr Med Assoc J"},{"key":"6497_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.028","volume":"297","author":"C Mendoza-Pinto","year":"2020","unstructured":"Mendoza-Pinto C, Rojas-Villarraga A, Molano-Gonz\u00e1lez N, Garc\u00eda-Carrasco M, Mungu\u00eda-Realpozo P, Etchegaray-Morales I et al (2020) Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Atherosclerosis 297:55\u201363. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.01.028","journal-title":"Atherosclerosis"},{"key":"6497_CR15","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1038\/s41598-017-07574-1","volume":"7","author":"A Mak","year":"2017","unstructured":"Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH (2017) Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep 7:7320. https:\/\/doi.org\/10.1038\/s41598-017-07574-1","journal-title":"Sci Rep"},{"key":"6497_CR16","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3402","volume":"13","author":"W Plazak","year":"2011","unstructured":"Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P et al (2011) Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 13:R117. https:\/\/doi.org\/10.1186\/ar3402","journal-title":"Arthritis Res Ther"},{"key":"6497_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3899\/jrheum.090312","volume":"36","author":"K-H Yiu","year":"2009","unstructured":"Yiu K-H, Wang S, Mok M-Y, Ooi GC, Khong P-L, Mak K-FH et al (2009) Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 36:2212\u20137. https:\/\/doi.org\/10.3899\/jrheum.090312","journal-title":"J Rheumatol"},{"key":"6497_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/rheumatology\/kep102","volume":"48","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ, Gonz\u00e1lez LA, Zhang J, Burgos PI, Reveille JD, Vil\u00e1 LM et al (2009) Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 48:817\u2013822. https:\/\/doi.org\/10.1093\/rheumatology\/kep102","journal-title":"Rheumatology (Oxford)"},{"issue":"1490\u20134","key":"6497_CR19","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1016\/s0002-9149(99)00130-7","volume":"83","author":"CJ Glueck","year":"1999","unstructured":"Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P (1999) Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol 83(1490\u20134):A8. https:\/\/doi.org\/10.1016\/s0002-9149(99)00130-7","journal-title":"Am J Cardiol"},{"key":"6497_CR20","unstructured":"Roitt I (2006) Autoimmunity and autoimmune diseases. Male D, Brostoff J, Roth D, editors. London: Mosby Elsevier; 375"},{"key":"6497_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/096120339500400304","volume":"4","author":"M Le Tonqu\u00e8ze","year":"1995","unstructured":"Le Tonqu\u00e8ze M, Salozhin K, Dueymes M, Piette JC, Kovalev V, Shoenfeld Y et al (1995) Role of beta 2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 4:179\u2013186. https:\/\/doi.org\/10.1177\/096120339500400304","journal-title":"Lupus"},{"key":"6497_CR22","first-page":"228","volume":"18","author":"A Mazurek","year":"2016","unstructured":"Mazurek A, Iwaniec T, Olszowska M, Perricone C, Widlinska B, Podolec P et al (2016) Antiphospholipid and antinuclear antibodies in young patients after myocardial revascularization procedures. Isr Med Assoc J 18:228\u2013231","journal-title":"Isr Med Assoc J"},{"key":"6497_CR23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s10067-018-4104-4","volume":"37","author":"K Buga\u0142a","year":"2018","unstructured":"Buga\u0142a K, Mazurek A, Gryga K, Komar M, Kope\u0107 G, Musia\u0142 J et al (2018) Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 37:2087\u20132093. https:\/\/doi.org\/10.1007\/s10067-018-4104-4","journal-title":"Clin Rheumatol"},{"key":"6497_CR24","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/01.CIR.0000158665.27783.0C","volume":"111","author":"S Steiner","year":"2005","unstructured":"Steiner S, Speidl WS, Pleiner J, Seidinger D, Zorn G, Kaun C et al (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841\u20131846. https:\/\/doi.org\/10.1161\/01.CIR.0000158665.27783.0C","journal-title":"Circulation"},{"key":"6497_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijcard.2005.08.001","volume":"111","author":"T K\u00e4lsch","year":"2006","unstructured":"K\u00e4lsch T, Nguyen XD, Elmas E, Grebert N, S\u00fcselbeck T, Kl\u00fcter H et al (2006) Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina. Int J Cardiol 111:217\u2013223. https:\/\/doi.org\/10.1016\/j.ijcard.2005.08.001","journal-title":"Int J Cardiol"},{"key":"6497_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1540-8167.2005.40738.x","volume":"16","author":"T K\u00e4lsch","year":"2005","unstructured":"K\u00e4lsch T, Elmas E, Nguyen XD, Grebert N, Wolpert C, Kl\u00fcter H et al (2005) Enhanced coagulation activation by in vitro lipopolysaccharide challenge in patients with ventricular fibrillation complicating acute myocardial infarction. J Cardiovasc Electrophysiol 16:858\u2013863. https:\/\/doi.org\/10.1111\/j.1540-8167.2005.40738.x","journal-title":"J Cardiovasc Electrophysiol"},{"key":"6497_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00395-005-0540-9","volume":"100","author":"AK G\u00f6tz","year":"2005","unstructured":"G\u00f6tz AK, Zahler S, Stumpf P, Welsch U, Becker BF (2005) Intracoronary formation and retention of micro aggregates of leukocytes and platelets contribute to postischemic myocardial dysfunction. Basic Res Cardiol 100:413\u2013421. https:\/\/doi.org\/10.1007\/s00395-005-0540-9","journal-title":"Basic Res Cardiol"},{"key":"6497_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/path.1711710311","volume":"171","author":"MJ Davies","year":"1993","unstructured":"Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D et al (1993) The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171:223\u2013229. https:\/\/doi.org\/10.1002\/path.1711710311","journal-title":"J Pathol"},{"key":"6497_CR29","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1074\/jbc.M009705200","volume":"276","author":"I Kim","year":"2001","unstructured":"Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276:7614\u20137620. https:\/\/doi.org\/10.1074\/jbc.M009705200","journal-title":"J Biol Chem"},{"key":"6497_CR30","first-page":"823","volume":"35","author":"K-J Kim","year":"2017","unstructured":"Kim K-J, Baek I-W, Yoon C-H, Kim W-U, Cho C-S (2017) Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 35:823\u2013830","journal-title":"Clin Exp Rheumatol"},{"key":"6497_CR31","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1161\/01.cir.96.12.4219","volume":"96","author":"SJ Hwang","year":"1997","unstructured":"Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AMJ et al (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96:4219\u20134225. https:\/\/doi.org\/10.1161\/01.cir.96.12.4219","journal-title":"Circulation"},{"key":"6497_CR32","first-page":"889","volume":"140","author":"P OYu","year":"1992","unstructured":"OYu P, Peclo MM, Gown AM (1992) Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. Am J Pathol 140:889\u201396","journal-title":"Am J Pathol"},{"key":"6497_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0008-6363(97)00143-0","volume":"36","author":"K Miwa","year":"1997","unstructured":"Miwa K, Igawa A, Inoue H (1997) Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc Res 36:37\u201344. https:\/\/doi.org\/10.1016\/s0008-6363(97)00143-0","journal-title":"Cardiovasc Res"},{"key":"6497_CR34","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1002\/art.34504","volume":"64","author":"SG Thacker","year":"2012","unstructured":"Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A et al (2012) Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 64:2975\u20132985. https:\/\/doi.org\/10.1002\/art.34504","journal-title":"Arthritis Rheum"},{"key":"6497_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/art.30165","volume":"63","author":"J Li","year":"2011","unstructured":"Li J, Fu Q, Cui H, Qu B, Pan W, Shen N et al (2011) Interferon-\u03b1 priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-\u03b1 and atherosclerosis in lupus. Arthritis Rheum 63:492\u2013502. https:\/\/doi.org\/10.1002\/art.30165","journal-title":"Arthritis Rheum"},{"key":"6497_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1172\/JCI112560","volume":"78","author":"EJ Bowie","year":"1986","unstructured":"Bowie EJ, Solberg LAJ, Fass DN, Johnson CM, Knutson GJ, Stewart ML et al (1986) Transplantation of normal bone marrow into a pig with severe von Willebrand\u2019s disease. J Clin Invest 78:26\u201330. https:\/\/doi.org\/10.1172\/JCI112560","journal-title":"J Clin Invest"},{"key":"6497_CR37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","volume":"4","author":"UM Vischer","year":"2006","unstructured":"Vischer UM (2006) von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 4:1186\u20131193. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01949.x","journal-title":"J Thromb Haemost"},{"key":"6497_CR38","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.v98.5.1424","volume":"98","author":"N Methia","year":"2001","unstructured":"Methia N, Andr\u00e9 P, Denis CV, Economopoulos M, Wagner DD (2001) Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 98:1424\u20131428. https:\/\/doi.org\/10.1182\/blood.v98.5.1424","journal-title":"Blood"},{"key":"6497_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/01.atv.5.1.67","volume":"5","author":"V Fuster","year":"1985","unstructured":"Fuster V, Lie JT, Badimon L, Rosemark JA, Badimon JJ, Bowie EJ (1985) Spontaneous and diet-induced coronary atherosclerosis in normal swine and swine with von Willebrand disease. Arteriosclerosis 5:67\u201373. https:\/\/doi.org\/10.1161\/01.atv.5.1.67","journal-title":"Arteriosclerosis"},{"key":"6497_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1517\/14728222.2013.840585","volume":"18","author":"S Montoro-Garc\u00eda","year":"2014","unstructured":"Montoro-Garc\u00eda S, Shantsila E, Lip GYH (2014) Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. Expert Opin Ther Targets 18:43\u201353. https:\/\/doi.org\/10.1517\/14728222.2013.840585","journal-title":"Expert Opin Ther Targets"},{"key":"6497_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.blre.2014.04.003","volume":"28","author":"MAH Sonneveld","year":"2014","unstructured":"Sonneveld MAH, de Maat MPM, Leebeek FWG (2014) Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 28:167\u2013178. https:\/\/doi.org\/10.1016\/j.blre.2014.04.003","journal-title":"Blood Rev"},{"key":"6497_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","volume":"117","author":"AO Spiel","year":"2008","unstructured":"Spiel AO, Gilbert JC, Jilma B (2008) von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117:1449\u20131459. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.722827","journal-title":"Circulation"},{"key":"6497_CR43","doi-asserted-by":"publisher","first-page":"e000107","DOI":"10.1136\/lupus-2015-000107","volume":"3","author":"V Domingues","year":"2016","unstructured":"Domingues V, Magder LS, Petri M (2016) Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med 3:e000107. https:\/\/doi.org\/10.1136\/lupus-2015-000107","journal-title":"Lupus Sci Med"},{"key":"6497_CR44","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1055\/s-0037-1613858","volume":"83","author":"BE van Aken","year":"2000","unstructured":"van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH (2000) Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83:536\u2013539","journal-title":"Thromb Haemost"},{"key":"6497_CR45","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood-2009-09-244426","volume":"115","author":"K Devreese","year":"2010","unstructured":"Devreese K, Peerlinck K, Hoylaerts MF (2010) Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 115:870\u2013878. https:\/\/doi.org\/10.1182\/blood-2009-09-244426","journal-title":"Blood"},{"key":"6497_CR46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.thromres.2015.08.019","volume":"136","author":"T Del Ross","year":"2015","unstructured":"Del Ross T, Ruffatti A, Cuffaro S, Tonello M, Calligaro A, Favaro M et al (2015) The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thromb Res 136:883\u2013886. https:\/\/doi.org\/10.1016\/j.thromres.2015.08.019","journal-title":"Thromb Res"},{"key":"6497_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.amjmed.2013.12.003","volume":"127","author":"G Lindner","year":"2014","unstructured":"Lindner G, Funk G-C, Pfortmueller CA, Leichtle AB, Fiedler GM, Schwarz C et al (2014) D-dimer to rule out pulmonary embolism in renal insufficiency. Am J Med 127:343\u2013347. https:\/\/doi.org\/10.1016\/j.amjmed.2013.12.003","journal-title":"Am J Med"},{"key":"6497_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.amjmed.2009.09.011","volume":"123","author":"J Thachil","year":"2010","unstructured":"Thachil J, Fitzmaurice DA, Toh CH (2010) Appropriate use of D-dimer in hospital patients. Am J Med 123:17\u201319. https:\/\/doi.org\/10.1016\/j.amjmed.2009.09.011","journal-title":"Am J Med"},{"key":"6497_CR49","doi-asserted-by":"publisher","unstructured":"Aguilar C, del Villar V (2005) Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis. Vol. 5, Br J Haematol 803\u20134; author reply 805. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05686.x","DOI":"10.1111\/j.1365-2141.2005.05686.x"},{"key":"6497_CR50","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0090-1229(92)90225-d","volume":"63","author":"AE Kabakov","year":"1992","unstructured":"Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN (1992) The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 63:214\u2013220. https:\/\/doi.org\/10.1016\/0090-1229(92)90225-d","journal-title":"Clin Immunol Immunopathol"},{"key":"6497_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/ard.61.2.110","volume":"61","author":"DJ Grainger","year":"2002","unstructured":"Grainger DJ, Bethell HWL (2002) High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis 61:110\u2013114. https:\/\/doi.org\/10.1136\/ard.61.2.110","journal-title":"Ann Rheum Dis"},{"key":"6497_CR52","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.22265","volume":"54","author":"A Farzaneh-Far","year":"2006","unstructured":"Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK et al (2006) Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 54:3918\u20133925. https:\/\/doi.org\/10.1002\/art.22265","journal-title":"Arthritis Rheum"},{"key":"6497_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12016-007-0013-z","volume":"32","author":"M-C Amigo","year":"2007","unstructured":"Amigo M-C (2007) The heart and APS. Clin Rev Allergy Immunol 32:178\u2013183. https:\/\/doi.org\/10.1007\/s12016-007-0013-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"6497_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00002281-200309000-00001","volume":"15","author":"AH Kao","year":"2003","unstructured":"Kao AH, Sabatine JM, Manzi S (2003) Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 15:519\u2013527. https:\/\/doi.org\/10.1097\/00002281-200309000-00001","journal-title":"Curr Opin Rheumatol"},{"key":"6497_CR55","first-page":"1789","volume":"35","author":"YH Rho","year":"2008","unstructured":"Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T et al (2008) Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 35:1789\u20131794","journal-title":"J Rheumatol"},{"key":"6497_CR56","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0008-6363(97)00039-4","volume":"34","author":"GY Lip","year":"1997","unstructured":"Lip GY, Blann A (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34:255\u2013265. https:\/\/doi.org\/10.1016\/s0008-6363(97)00039-4","journal-title":"Cardiovasc Res"},{"issue":"1","key":"6497_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5114\/aoms.2019.90271","volume":"18","author":"A Mazurek","year":"2022","unstructured":"Mazurek A, Gryga K, Bugala K, Iwaniec T, Musial J, Podolec P et al (2022) Influence of statin therapy on antiphospholipid antibodies and endothelial dysfunction in young patients with coronary artery disease and systemic lupus erythematosus. Arch Med Sci 18(1):18\u201324. https:\/\/doi.org\/10.5114\/aoms.2019.90271","journal-title":"Arch Med Sci"},{"key":"6497_CR58","first-page":"75","volume":"1","author":"DI Feinstein","year":"1972","unstructured":"Feinstein DI, Rapaport SI (1972) Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1:75\u201395","journal-title":"Prog Hemost Thromb"},{"key":"6497_CR59","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/rheumatology\/26.5.324","volume":"26","author":"EN Harris","year":"1987","unstructured":"Harris EN (1987) Syndrome of the black swan. Br J Rheumatol 26:324\u2013326. https:\/\/doi.org\/10.1093\/rheumatology\/26.5.324","journal-title":"Br J Rheumatol"},{"key":"6497_CR60","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309\u20131311. https:\/\/doi.org\/10.1002\/1529-0131(199907)42:7%3c1309::AID-ANR1%3e3.0.CO;2-F","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6497_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"6497_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2796.2011.02362.x","volume":"270","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, de Groot PG, Pengo V (2011) Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 270(2):110\u2013122. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02362.x","journal-title":"J Intern Med"},{"key":"6497_CR63","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1055\/s-0038-1657710","volume":"78","author":"J Musia\u0142","year":"1997","unstructured":"Musia\u0142 J, Swad\u017aba J, Jankowski M, Grzywacz M, Bazan-Socha S, Szczeklik A (1997) Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 78:1173\u20131177","journal-title":"Thromb Haemost"},{"key":"6497_CR64","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1055\/a-1701-2809","volume":"122","author":"D Green","year":"2022","unstructured":"Green D (2022) Pathophysiology of antiphospholipid syndrome. Thromb Haemost 122:1085\u20131095. https:\/\/doi.org\/10.1055\/a-1701-2809","journal-title":"Thromb Haemost"},{"issue":"4","key":"6497_CR65","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019\u20131027. https:\/\/doi.org\/10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"key":"6497_CR66","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827\u20131832. https:\/\/doi.org\/10.1182\/blood-2002-02-0441","journal-title":"Blood"},{"key":"6497_CR67","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1111\/j.1538-7836.2007.02669.x","volume":"5","author":"J Swad\u017aba","year":"2007","unstructured":"Swad\u017aba J, Iwaniec T, Szczeklik A, Musia\u0142 J (2007) Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost 5:1883\u20131889. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02669.x","journal-title":"J Thromb Haemost"},{"key":"6497_CR68","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/0961203311399607","volume":"20","author":"W Plazak","year":"2011","unstructured":"Plazak W, Gryga K, Milewski M, Podolec M, Kostkiewicz M, Podolec P et al (2011) Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 20:936\u2013944. https:\/\/doi.org\/10.1177\/0961203311399607","journal-title":"Lupus"},{"key":"6497_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00296-009-1255-2","volume":"31","author":"A Cefle","year":"2011","unstructured":"Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31:183\u2013189. https:\/\/doi.org\/10.1007\/s00296-009-1255-2","journal-title":"Rheumatol Int"},{"key":"6497_CR70","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0961203308101719","volume":"18","author":"EM Hasegawa","year":"2009","unstructured":"Hasegawa EM, Caleiro MTC, Fuller R, Carvalho JF (2009) The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 18:618\u2013621. https:\/\/doi.org\/10.1177\/0961203308101719","journal-title":"Lupus"},{"key":"6497_CR71","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","volume":"379","author":"B Z\u00f6ller","year":"2012","unstructured":"Z\u00f6ller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet (London England) 379:244\u2013249. https:\/\/doi.org\/10.1016\/S0140-6736(11)61306-8","journal-title":"Lancet (London England)"},{"key":"6497_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0167-5273(03)00106-2","volume":"92","author":"C-C Lin","year":"2003","unstructured":"Lin C-C, Ding H-J, Chen Y-W, Wang J-J, Ho S-T, Kao A (2003) Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 92:157\u2013161. https:\/\/doi.org\/10.1016\/s0167-5273(03)00106-2","journal-title":"Int J Cardiol"},{"key":"6497_CR73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1536\/jhj.44.83","volume":"44","author":"J-J Lin","year":"2003","unstructured":"Lin J-J, Hsu H-B, Sun S-S, Wang J-J, Ho S-T, Kao C-H (2003) Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus\u2013a preliminary report. Jpn Heart J 44:83\u201389. https:\/\/doi.org\/10.1536\/jhj.44.83","journal-title":"Jpn Heart J"},{"key":"6497_CR74","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.thromres.2004.07.012","volume":"114","author":"M Petri","year":"2004","unstructured":"Petri M (2004) The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 114:593\u2013595. https:\/\/doi.org\/10.1016\/j.thromres.2004.07.012","journal-title":"Thromb Res"},{"key":"6497_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0906-6705.2004.00208.x","volume":"13","author":"MR Namazi","year":"2004","unstructured":"Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13:337\u2013339. https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00208.x","journal-title":"Exp Dermatol"},{"key":"6497_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.carrev.2009.11.001","volume":"12","author":"M Chyrchel","year":"2011","unstructured":"Chyrchel M, Dudek D, Rzeszutko L, Dziewierz A, Chyrchel B, Rakowski T et al (2011) Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. Cardiovasc Revasc Med 12:2\u20139. https:\/\/doi.org\/10.1016\/j.carrev.2009.11.001","journal-title":"Cardiovasc Revasc Med"},{"key":"6497_CR77","first-page":"315","volume":"1","author":"D Dudek","year":"2005","unstructured":"Dudek D, Heba G, Legutko J, Chyrchel M, Rakowski T, Kaluza GL et al (2005) Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina. EuroIntervention 1:315\u2013320","journal-title":"EuroIntervention"},{"key":"6497_CR78","first-page":"213","volume":"61","author":"M Chyrchel","year":"2004","unstructured":"Chyrchel M, Dudek D, Bartu\u015b S, Legutko J, Heba G, Dubiel JS (2004) High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina. Kardiol Pol 61:213\u2013214","journal-title":"Kardiol Pol"},{"key":"6497_CR79","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","volume":"363","author":"DW McCarey","year":"2004","unstructured":"McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (London England) 363:2015\u20132021. https:\/\/doi.org\/10.1016\/S0140-6736(04)16449-0","journal-title":"Lancet (London England)"},{"key":"6497_CR80","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.4049\/jimmunol.173.12.7641","volume":"173","author":"S Lawman","year":"2004","unstructured":"Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black\/white F1 mice. J Immunol 173:7641\u20137646. https:\/\/doi.org\/10.4049\/jimmunol.173.12.7641","journal-title":"J Immunol"},{"key":"6497_CR81","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1191\/0961203303lu429oa","volume":"12","author":"C Abud-Mendoza","year":"2003","unstructured":"Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonz\u00e1lez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607\u2013611. https:\/\/doi.org\/10.1191\/0961203303lu429oa","journal-title":"Lupus"},{"key":"6497_CR82","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1136\/ard.2003.018333","volume":"63","author":"S Van Doornum","year":"2004","unstructured":"Van Doornum S, McColl G, Wicks IP (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63:1571\u20131575. https:\/\/doi.org\/10.1136\/ard.2003.018333","journal-title":"Ann Rheum Dis"},{"key":"6497_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5114\/reum.2022.117836","volume":"60","author":"H Dziedzic-Oleksy","year":"2022","unstructured":"Dziedzic-Oleksy H, Mazurek A, Buga\u0142a K, Perricone C, Drabik L, P\u0142azak W (2022) Arterial stiffness and atherosclerosis in systemic lupus erythematosus patients. Reumatologia 60:165\u2013172. https:\/\/doi.org\/10.5114\/reum.2022.117836","journal-title":"Reumatologia"},{"key":"6497_CR84","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jacc.2004.11.006","volume":"45","author":"F Hermann","year":"2005","unstructured":"Hermann F, Forster A, Chenevard R, Enseleit F, H\u00fcrlimann D, Corti R et al (2005) Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45:461\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2004.11.006","journal-title":"J Am Coll Cardiol"},{"key":"6497_CR85","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0140-6736(05)60116-X","volume":"352","author":"J Hanson","year":"1998","unstructured":"Hanson J, Bossingham D (1998) Lupus-like syndrome associated with simvastatin. Lancet (London England) 352:1070. https:\/\/doi.org\/10.1016\/S0140-6736(05)60116-X","journal-title":"Lancet (London England)"},{"key":"6497_CR86","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/s0002-9343(01)00711-2","volume":"110","author":"B No\u00ebl","year":"2001","unstructured":"No\u00ebl B, Cerottini JP, Panizzon RG (2001) Atorvastatin-induced dermatomyositis. Am J Med 110:670\u20131. https:\/\/doi.org\/10.1016\/s0002-9343(01)00711-2","journal-title":"Am J Med"},{"key":"6497_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20\u201328. https:\/\/doi.org\/10.1056\/NEJMoa042378","journal-title":"N Engl J Med"},{"key":"6497_CR88","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard.2010.136762","volume":"70","author":"MA Petri","year":"2011","unstructured":"Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS (2011) Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis 70:760\u2013765. https:\/\/doi.org\/10.1136\/ard.2010.136762","journal-title":"Ann Rheum Dis"},{"key":"6497_CR89","doi-asserted-by":"publisher","first-page":"n693","DOI":"10.1136\/bmj.n693","volume":"372","author":"D Ayoubkhani","year":"2021","unstructured":"Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I et al (2021) Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 372:n693. https:\/\/doi.org\/10.1136\/bmj.n693","journal-title":"BMJ"},{"key":"6497_CR90","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/archinte.1992.00400170157032","volume":"152","author":"B Bannwarth","year":"1992","unstructured":"Bannwarth B, Miremont G, Papapietro PM (1992) Lupuslike syndrome associated with simvastatin. Arch Intern Med 152:1093","journal-title":"Arch Intern Med"},{"key":"6497_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archderm.139.1.45","volume":"139","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R et al (2003) Drug-induced, Ro\/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 139:45\u201349. https:\/\/doi.org\/10.1001\/archderm.139.1.45","journal-title":"Arch Dermatol"},{"key":"6497_CR92","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keh035","volume":"43","author":"B No\u00ebl","year":"2004","unstructured":"No\u00ebl B (2004) Statins and lupus erythematosus. Rheumatol (Oxford England) 43:397\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keh035","journal-title":"Rheumatol (Oxford England)"},{"key":"6497_CR93","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/82219","volume":"6","author":"B Kwak","year":"2000","unstructured":"Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399\u20131402. https:\/\/doi.org\/10.1038\/82219","journal-title":"Nat Med"},{"key":"6497_CR94","doi-asserted-by":"publisher","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","volume":"54","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al (2019) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of. Eur Respir J 54:1901647. https:\/\/doi.org\/10.1183\/13993003.01647-2019","journal-title":"Eur Respir J"},{"key":"6497_CR95","first-page":"985","volume":"188","author":"C Haas","year":"2004","unstructured":"Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188:985\u201397 (discussion 997)","journal-title":"Bull Acad Natl Med"},{"key":"6497_CR96","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1148\/radiol.2531082137","volume":"252","author":"C Uebleis","year":"2009","unstructured":"Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M et al (2009) Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring\u2013long-term follow-up. Radiology 252:682\u2013690. https:\/\/doi.org\/10.1148\/radiol.2531082137","journal-title":"Radiology"},{"key":"6497_CR97","first-page":"1560","volume":"31","author":"JA Gir\u00f3n-Gonz\u00e1lez","year":"2004","unstructured":"Gir\u00f3n-Gonz\u00e1lez JA, Garc\u00edadel R\u00edo E, Rodr\u00edguez C, Rodr\u00edguez-Martorell J, Serrano A (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31:1560\u20137","journal-title":"J Rheumatol"},{"key":"6497_CR98","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1001\/archinte.160.13.2042","volume":"160","author":"DG Wahl","year":"2000","unstructured":"Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160:2042\u20132048. https:\/\/doi.org\/10.1001\/archinte.160.13.2042","journal-title":"Arch Intern Med"},{"key":"6497_CR99","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.7861\/clinmed.2020-0440","volume":"20","author":"TA Slater","year":"2020","unstructured":"Slater TA, Straw S, Drozd M, Kamalathasan S, Cowley A, Witte KK (2020) Dying \u201cdue to\u201d or \u201cwith\u201d COVID-19: a cause of death analysis in hospitalised patients. Clin Med 20:e189\u2013e190. https:\/\/doi.org\/10.7861\/clinmed.2020-0440","journal-title":"Clin Med"},{"key":"6497_CR100","doi-asserted-by":"publisher","unstructured":"Wu C, Liu Y, Cai X, Zhang W, Li Y, Fu C (2021) Prevalence of venous thromboembolism in critically ill patients with coronavirus disease 2019: a meta-analysis. Front Med 603558 https:\/\/doi.org\/10.3389\/fmed.2021.603558","DOI":"10.3389\/fmed.2021.603558"},{"key":"6497_CR101","doi-asserted-by":"publisher","unstructured":"Drabik L, Derbisz J, Chatys-Bogacka Z, Mazurkiewicz I, Sawczynska K, Kesek T et al (2022) Neurological prognostic factors in hospitalized patients with COVID-19. Brain Sci 12(2) https:\/\/doi.org\/10.3390\/brainsci12020193","DOI":"10.3390\/brainsci12020193"},{"key":"6497_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5603\/pjnns.a2021.0039","volume":"55","author":"M Wnuk","year":"2021","unstructured":"Wnuk M, Sawczy\u0144ska K, K\u0119sek T, Wrona P, Chatys-Bogacka \u017b, Mazurkiewicz I et al (2021) Neurological symptoms in hospitalised patients with COVID-19 and their association with in-hospital mortality. Neurol Neurochir Pol 55:1\u20138. https:\/\/doi.org\/10.5603\/pjnns.a2021.0039","journal-title":"Neurol Neurochir Pol"},{"key":"6497_CR103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-020-02134-3","volume":"50","author":"RC Becker","year":"2020","unstructured":"Becker RC (2020) COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 50:54\u201367. https:\/\/doi.org\/10.1007\/s11239-020-02134-3","journal-title":"J Thromb Thrombolysis"},{"key":"6497_CR104","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jth.15016","volume":"18","author":"C Nougier","year":"2020","unstructured":"Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L et al (2020) Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 18:2215\u20132219. https:\/\/doi.org\/10.1111\/jth.15016","journal-title":"J Thromb Haemost"},{"key":"6497_CR105","doi-asserted-by":"publisher","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","volume":"20","author":"A Dotan","year":"2021","unstructured":"Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20:102792. https:\/\/doi.org\/10.1016\/j.autrev.2021.102792","journal-title":"Autoimmun Rev"},{"key":"6497_CR106","unstructured":"National Institute for Health and Care Excellence, Practitioners RC of G, Scotland HI. COVID-19 rapid guideline\u202f: managing the long-term effects of COVID-19. NICE Guidel. 2020;(18 December 2020):1\u201335."},{"key":"6497_CR107","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/thoraxjnl-2020-215818","volume":"76","author":"S Mandal","year":"2021","unstructured":"Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS et al (2021) \u201cLong-COVID\u201d: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76:396\u2013398. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215818","journal-title":"Thorax"},{"key":"6497_CR108","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jama.2020.21465","volume":"325","author":"JP Donnelly","year":"2021","unstructured":"Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC (2021) Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. JAMA 325:304\u2013306. https:\/\/doi.org\/10.1001\/jama.2020.21465","journal-title":"JAMA"},{"key":"6497_CR109","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1017\/S0950268821000145","volume":"149","author":"S Venturelli","year":"2021","unstructured":"Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G et al (2021) Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol Infect 149:e32. https:\/\/doi.org\/10.1017\/S0950268821000145","journal-title":"Epidemiol Infect"},{"key":"6497_CR110","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jth.15267","volume":"19","author":"L Townsend","year":"2021","unstructured":"Townsend L, Fogarty H, Dyer A, Martin-Loeches I, Bannan C, Nadarajan P et al (2021) Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost 19:1064\u20131070. https:\/\/doi.org\/10.1111\/jth.15267","journal-title":"J Thromb Haemost"},{"key":"6497_CR111","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/qjmed\/hcab054","volume":"114","author":"M Zuin","year":"2021","unstructured":"Zuin M, Rigatelli G, Zuliani G, Roncon L (2021) The risk of thrombosis after acute-COVID-19 infection. QJM 114:619\u2013620. https:\/\/doi.org\/10.1093\/qjmed\/hcab054","journal-title":"QJM"},{"key":"6497_CR112","doi-asserted-by":"publisher","first-page":"e64909","DOI":"10.7554\/eLife.64909","volume":"10","author":"FW Chioh","year":"2021","unstructured":"Chioh FW, Fong S-W, Young BE, Wu K-X, Siau A, Krishnan S et al (2021) Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife 10:e64909. https:\/\/doi.org\/10.7554\/eLife.64909","journal-title":"Elife"},{"key":"6497_CR113","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10067-021-05691-x","volume":"40","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Zimba O, Gasparyan AY (2021) COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol 40:2611\u20132619. https:\/\/doi.org\/10.1007\/s10067-021-05691-x","journal-title":"Clin Rheumatol"},{"key":"6497_CR114","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England) 395:1417\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30937-5","journal-title":"Lancet (London, England)"},{"key":"6497_CR115","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/infdis\/jiaa349","volume":"222","author":"M Tong","year":"2020","unstructured":"Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F et al (2020) Elevated expression of serum endothelial cell adhesion molecules in COVID-19 patients. J Infect Dis 222:894\u2013898. https:\/\/doi.org\/10.1093\/infdis\/jiaa349","journal-title":"J Infect Dis"},{"key":"6497_CR116","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/infdis\/jiaa528","volume":"222","author":"C Guervilly","year":"2020","unstructured":"Guervilly C, Burtey S, Sabatier F, Cauchois R, Lano G, Abdili E et al (2020) Circulating endothelial cells as a marker of endothelial injury in severe COVID -19. J Infect Dis 222:1789\u20131793. https:\/\/doi.org\/10.1093\/infdis\/jiaa528","journal-title":"J Infect Dis"},{"key":"6497_CR117","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jinf.2020.11.041","volume":"82","author":"E Falcinelli","year":"2021","unstructured":"Falcinelli E, Petito E, Becattini C, De Robertis E, Paliani U, Sebastiano M et al (2021) Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients. J Infect 82:186\u2013230. https:\/\/doi.org\/10.1016\/j.jinf.2020.11.041","journal-title":"J Infect"},{"key":"6497_CR118","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s11739-020-02443-8","volume":"15","author":"S Coccheri","year":"2020","unstructured":"Coccheri S (2020) COVID-19: The crucial role of blood coagulation and fibrinolysis. Intern Emerg Med 15:1369\u20131373. https:\/\/doi.org\/10.1007\/s11739-020-02443-8","journal-title":"Intern Emerg Med"},{"issue":"1","key":"6497_CR119","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cjca.2019.08.001","volume":"36","author":"L Drabik","year":"2020","unstructured":"Drabik L, Konieczy\u0144ska M, Undas A (2020) Clot lysis time predicts stroke during anticoagulant therapy in patients with atrial fibrillation. Can J Cardiol 36(1):119\u2013126. https:\/\/doi.org\/10.1016\/j.cjca.2019.08.001","journal-title":"Can J Cardiol"},{"key":"6497_CR120","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.thromres.2015.05.028","volume":"136","author":"L Drabik","year":"2015","unstructured":"Drabik L, Wo\u0142kow P, Undas A (2015) Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation. Thromb Res 136:408\u2013414. https:\/\/doi.org\/10.1016\/j.thromres.2015.05.028","journal-title":"Thromb Res"},{"key":"6497_CR121","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10456-020-09762-6","volume":"24","author":"A Philippe","year":"2021","unstructured":"Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N et al (2021) Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24:505\u2013517. https:\/\/doi.org\/10.1007\/s10456-020-09762-6","journal-title":"Angiogenesis"},{"key":"6497_CR122","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjh.17273","volume":"192","author":"SE Ward","year":"2021","unstructured":"Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL et al (2021) Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol 192:714\u2013719. https:\/\/doi.org\/10.1111\/bjh.17273","journal-title":"Br J Haematol"},{"key":"6497_CR123","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jth.15191","volume":"19","author":"I Mancini","year":"2021","unstructured":"Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G et al (2021) The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 19:513\u2013521. https:\/\/doi.org\/10.1111\/jth.15191","journal-title":"J Thromb Haemost"},{"key":"6497_CR124","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10456-021-09789-3","volume":"24","author":"A Philippe","year":"2021","unstructured":"Philippe A, Gendron N, Bory O, Beauvais A, Mirault T, Planquette B et al (2021) Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF\/ADAMTS13 ratio imbalance. Angiogenesis 24:407\u201311. https:\/\/doi.org\/10.1007\/s10456-021-09789-3","journal-title":"Angiogenesis"},{"key":"6497_CR125","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1111\/jth.14994","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, Linskens EA, Benoit D, Peperstraete H (2020) Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost 18:2191\u20132201. https:\/\/doi.org\/10.1111\/jth.14994","journal-title":"J Thromb Haemost"},{"key":"6497_CR126","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s10067-021-05724-5","volume":"40","author":"D Castillo-Mart\u00ednez","year":"2021","unstructured":"Castillo-Mart\u00ednez D, Torres Z, Amezcua-Guerra LM, Pineda C (2021) Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19? Clin Rheumatol 40:3015\u20133019. https:\/\/doi.org\/10.1007\/s10067-021-05724-5","journal-title":"Clin Rheumatol"},{"key":"6497_CR127","doi-asserted-by":"publisher","first-page":"584241","DOI":"10.3389\/fimmu.2020.584241","volume":"11","author":"MO Borghi","year":"2020","unstructured":"Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C et al (2020) Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol 11:584241. https:\/\/doi.org\/10.3389\/fimmu.2020.584241","journal-title":"Front Immunol"},{"key":"6497_CR128","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1002\/jmv.27077","volume":"93","author":"BM Henry","year":"2021","unstructured":"Henry BM, Szergyuk I, de Oliveira MHS, Lippi G, Benoit JL, Vikse J et al (2021) Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state. J Med Virol 93:5515\u20135522. https:\/\/doi.org\/10.1002\/jmv.27077","journal-title":"J Med Virol"},{"key":"6497_CR129","doi-asserted-by":"publisher","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","volume":"5","author":"A Java","year":"2020","unstructured":"Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH et al (2020) The complement system in COVID-19: friend and foe? JCI Insight 5:e140711. https:\/\/doi.org\/10.1172\/jci.insight.140711","journal-title":"JCI Insight"},{"key":"6497_CR130","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/ijms22020559","volume":"22","author":"J Klopf","year":"2021","unstructured":"Klopf J, Brostjan C, Eilenberg W, Neumayer C (2021) Neutrophil extracellular traps and their implications in cardiovascular and inflammatory disease. Int J Mol Sci 22:559. https:\/\/doi.org\/10.3390\/ijms22020559","journal-title":"Int J Mol Sci"},{"key":"6497_CR131","doi-asserted-by":"publisher","first-page":"e138999","DOI":"10.1172\/jci.insight.138999","volume":"5","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5:e138999. https:\/\/doi.org\/10.1172\/jci.insight.138999","journal-title":"JCI Insight"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06497-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:04:40Z","timestamp":1699866280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06497-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":131,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6497"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06497-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}